Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (8)

2021

  1. Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies

    Cancers, Vol. 13, Núm. 12

  2. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. Epigenetic SmAd3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma

    Cancer Research, Vol. 80, Núm. 2, pp. 276-290

  2. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

2019

  1. The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

    Cancers, Vol. 11, Núm. 11

2018

  1. Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm

    BMC Genomics, Vol. 19, Núm. 1

2017

  1. Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer

    Oncotarget, Vol. 8, Núm. 62, pp. 105196-105210

2013

  1. A prognostic DNA methylation signature for stage I non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 32, pp. 4140-4147